Ischemic versus idiopathic cardiomyopathy: Differing neurohumoral profiles despite comparable peak oxygen uptake

International Journal of Cardiology

Volumn 61, Issue 3, 1997, Pages 261-268

  Deng, Mario C ^a,b   Brisse, Betty ^a   Erren, Michael ^a   Khurana, Claudia ^a   Breithardt, Günter ^a   Scheld, Hans H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Klinik und Poliklinik fur Neurologie   (Germany)

Author keywords

Ischemic cardiomyopathy; Neurohormonal regulation; Spiroergometric testing; T cell immune response

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADRENALIN; ANGIOTENSIN; INTERLEUKIN 2 RECEPTOR; NORADRENALIN; RENIN;

ADULT; ARTICLE; CARDIOMYOPATHY; CATECHOLAMINE BLOOD LEVEL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; ERGOMETRY; FEMALE; HEART MUSCLE ISCHEMIA; HORMONAL REGULATION; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AGED; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CARDIOMYOPATHY, DILATED; EPINEPHRINE; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NOREPINEPHRINE; PILOT PROJECTS; RECEPTORS, INTERLEUKIN-2; REGRESSION ANALYSIS; RENIN; RENIN-ANGIOTENSIN SYSTEM; STATISTICS, NONPARAMETRIC; SYMPATHETIC NERVOUS SYSTEM; T-LYMPHOCYTES;

EID: 0030862005     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00163-0     Document Type: Article

References (67)

1. Stiles GL. A riddle wrapped in a mystery inside an enigma. Circulation 1995;92:1678-9.
2. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
3. Singh SN, Fletcher RD, Fisher SG et al. Survival trial of antiarrhythmic therapy in congestive heart failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-88.
4. CIBIS Investigators and Committee. A randomized trial of ß-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
5. Packer M, O'Connor CM, Ghali JK et al. PRAISE study group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
6. Breithardt G. Amiodarone in patients with heart failure (Editorial). N Engl J Med 1995;333:121-2.
7. Anderson JL, Carlquist JF, Hammond EH. Deficient natural killer cell activity in patients with idiopathic dilated cardiomyopathy. Lancet 1982;ii:1124-7.
8. Böhm M, Gierschik P, Jakobs KH, Schnabel P, Kemkes B, Erdmann E. Localization of a 'post-receptor defect' in human dilated cardiomyopathy. Am J Cardiol 1989;64:812-4.
9. 1-downregulalion in heart failure. Circ Res 1986;59:297-309.
10. 2 adrenergic receptor-mediated adenylate cyclase stimulation in non-failing and failing human ventricular myocardium. Mol Pharmacol 1989;35:295-303.
11. 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol 1986;8:1235-42.
12. Eckstein R, Mempel W, Bolte HD. Reduced suppressor cell activity in congestive cardiomyopathy and in myocarditis. Circulation 1982;65:1224-9.
13. Feldman AM, Cates AE, Veazey WB et al. Increase of the 40 000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 1988;82:189-97.
14. 1-proteins in heart failure. Lancet 1988;2:936-7.
15. Parker JD, Newton GE, Landzberg JS, Floras JS, Colucci WS. Functional significance of presynaptic α-adrenergic receptors in the failing and non-failing human left ventricle. Circulation 1995;92:1793-800.
16. Bristow MR, Ginsburg R, Minobe W et al. Decreased catecholamine sensitivity and ß-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
17. Ginsburg R, Bristow MR, Billingham ME, Stinson EB, Schroeder JS, Harrison DC. Study of the normal and failing isolated human heart: Decreased response of failing heart to isoproterenol. Am Heart J 1983;106:535-40.
18. Bristow MR, Anderson FL, Port D et al. Differences in ß-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:1024-39.
19. Woodley SL, Gilbert EM, Anderson JL et al. Differing effect of chronic ß-blockade with bucindolol on cardiac function in patients with idiopathic vs. ischemic cardiomyopathy (abstract). Circulation 1989;80(Suppl. IV)IV-11.
20. ia in human hearts with dilated but not ischemic cardiomyopathy. Circulation 1990;82:1249-65.
21. Beaver W, Wasserman K, Whipp B. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1987;60:2020-7.
22. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehab Med 1970;2-3:92-8.
23. Hunt SA. 24th Bethesda Conference: Cardiac Transplantation. J Am Coll Cardiol 1993;22,1:1-64
24. Mancini DM, Rein R, Mull R, et al. Value of peak exercise oxygen consumption to risk-stratify cardiac transplantation candidates. Circulation 1990;82:III-713
25. Mancini DM, Rein R, Mull R et al. Value of peak oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-83.
26. O'Connell JB, Bourge RC, Costanzo-Nordin MR et al. Cardiac Transplantation: Recipient Selection, Donor Procurement and Medical Followup. Circulation 1992;86:1061-79.
27. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-67.
28. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
29. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987;75(suppl4):80-92.
30. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
31. Kirlin PC, Grekin R, Das S, Ballor E, Johnson T, Pitt B. Neurohormonal activation during exercise in congestive heart failure. Am J Med 1986;81:623-9.
32. Matsumoto A, Hirata Y, Momomura SI et al. Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. Am Heart J 1995;129:139-45.
33. Stevenson LW, Steimle AE, Fonarow G et al. Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol 1995;25:163-70.
34. Bayliss J, Norell M, Canepa-Anson R, Poole-Wilson P, Sutton GC. Neuroendocrine and haemodynamic interactions at rest and during exercise in chronic heart failure: double-blind comparison of captopril and prazosin (abstract). Circulation 1984;70(Suppl. II):1673.
35. Bichet DG, Kortas C, Mettauer B et al. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 1986;29:1188-96.
36. Chidsey CA, Braunwald E. Sympathetic activity and neurotransmitter depletion in congestive heart failure. Pharmacol Rev 1966;18:685-700.
37. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962;267:650-4.
38. Cohn JN, Levine B, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med, 1984;311:819-23.
39. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-52.
40. Francis GS, Goldsmith SR, Ziesche SM, Cohn JN. Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am J Cardiol 1982;49:1152-6.
41. Nicklas JM, Benedict C, Johnstone DE et al. Relationship between neurohumoral profiles and one year mortality in patients with congestive heart failure and/or left ventricular dysfunction. Circulation 1991;84(4 (suppl.II)):II468.
42. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988;77:721-30.
43. 125] idocyanopindolol. Life Sci 1981;29:2189-98.
44. Felten DL, Felten SY, Bellinger DL et al. Noradrenergic sympathetic neural interactions with the immune system: structure and function. Immunol Rev 1987;100:1225-60.
45. Landmann RMA, Muller FB, Perini C, Wesp M, Erne P, Buhler FR. Changes of immunoregulatory cells induced by psychological and physical stress: Relationship to plasma catecholamines. Clin Exp Immunol 1984;58:127-35.
46. Maisel AS, Harris T, Rearden CA, Michel MC. ß-adrenergic receptors in lymphocyte subsets after exercise. Circulation 1990;82:2003-10.
47. Murray DR, Irwin M, Rearden CA, Ziegler M, Motulsky H, Maisel AS. Sympathetic and immune interaction during dynamic exercise: mediation via a ß-adrenergic independent mechanism. Circulation 1992;86:203-13.
48. Feldman RD, Hunninghake GW, McArdle WL. ß-adrenergic receptor mediated suppression of interleukin-2-receptors in human lymphocytes. J Immunol 1987;137:3355-9.
49. Crary B, Borysenko M, Sutherland DC, Kutz I, Borysenko JC, Benson H. Decrease in mitogen responsiveness of mononuclear cells from peripheral blood after epinephrine administration in humans. J Immunol 1983;130:694-7.
50. Crary B, Hauser SL, Borysenko M et al. Epinephrine-induced changes in the distribution of lymphocyte subsets in peripheral blood of humans. J Immunol 1983;131:1178-81.
51. 2-adrenergic, spleen-dependent process. Am J Physiol 1990;258:E191-202.
52. Bourne HR, Lichtenstein LM, Melmon KL, Henney CS, Weinstein Y, Shearer GM. Modulation of inflammation and immunity by cAMP: receptors for vasoactive hormones and mediators of inflammation regulate many leukocyte functions. Science 1974;184:19-28.
53. Hellstrand K, Hermodsson S, Strannegard O. Evidence for a β adrenoceptor mediated regulation of human natural killer cells. J Immunol 1985;134:4095-99.
54. Kammer GM. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of immune response. Immunol Today 1988;9:222-9.
55. Horton R, Antonipillai I, Natarajan R, Nadler J. The effect of tumor-necrosis-factor and interleukin-1 on the renin-angiotensin system (abstr). Clin Res 1989;37:532A.
56. Dzau VJ. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. Am J Cardiol 1992;70:4C-11C.
57. Maisel AS, Knowlton KU, Insel PA, Michel MC. Adrenergic control of circulating lymphocyte subpopulations: effects of congestive heart failure, dynamic exercise, and terbutaline treatment. J Clin Invest 1990;85:462-7.
58. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of sympathetic-induced alterations of immunologic function. Circulation 1994;90:1774-80.
59. Miossec P, Elhamiani M, Edmonds-Alt X, Sany J, Hirn M. Functional studies of soluble low-affinity interleukin-2 receptors in rheumatoid synovial fluid. Arthritis Rheum 1990;33:1688-94.
60. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure (editorial)? Circulation 1995;92:1379-82.
61. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Circulation 1989;80:65-77.
62. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989;13:134-42.
63. Van Veldhuisen DJ, ManIn'tVeld AJ, Dunselman PHJM, Lok DJA, Dohmen HJM, Poortermans JC, Withagen AJAM, Pasteuning WH, Brouwer J, Lie KI. On behalf of the DIMT study group. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch ibopamine multicenter trial (DIMT). J Am Coll Cardiol 1993;22:1564-73.
64. Daggett WM, Weisfeldt ML. Influence of the sympathetic nervous system on the response of the normal heart to digitalis. Am J Cardiol 1965;16:394-405.
65. Cooke JP, Shepherd JT, Vanhoutte PM. Vasoconstriction induced by ouabain in the canine coronary artery: contribution of adrenergic and nonadrenergic responses. Cardiovasc Drugs Ther 1988;2:255-63.
66. Gheorghiade M, Ferguson D. Digoxin: a neurohormonal modulator in heart failure? Circulation 1991;84:2181-6.
67. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995;92:1801-7.